Device developer Ryah Group, Inc. (CSE: RYAH) has had its smart medical cannabis inhaler approved by Canada’s federal regulator.
On Tuesday, the company said its Ryah Smart Inhaler received a Health Canada medical device licence through its subsidiary Ryah Medtech, Inc.
The licence covers the inhaler as well as its proprietary cartridges and software application. The inhaler is registered as a class 2 device, with class 1 being for lowest-risk devices and class 4 for high-risk devices like pacemakers.
The company says the licensing will drive more domestic sales, while helping to secure further device certifications internationally.
Ryah cites data from Statistics Canada that there are over 290,000 actively registered cannabis patients, and a total of 8 million citizens living with chronic pain. The firm says insurance reimbursement and various provincial programs like the Ontario Disability Support program are designed to lower or fully cover costs of certified medical devices.
Approval from Health Canada is a major step to achieving Ryah’s global footprint, says CEO Gregory Wagner.
“Once again, certification for both our software and hardware puts us in a unique position to provide objective data analytics which is critical for developing highly personalized cannabis therapies,” he said in a statement.
“We expect the Health Canada [medical device licence] will aid Ryah’s efforts to obtain additional country specific-certifications, including New Zealand, Australia and beyond.”
The Smart Inhaler allows patients specific dosing of dried cannabis formulations. Patients can also register their usage, and voluntarily provide anonymous data that Ryah says can be analyzed for regulatory improvements, research and awareness.